SCYX - scynexia
- Creatore Discussione renna63
- Data di inizio
renna63
Nuovo Utente
- Registrato
- 17/7/09
- Messaggi
- 2.816
- Punti reazioni
- 85
ocio al superamento del bordo sup della cloud.
SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update
PR NewswireMay 8, 2018
Enrollment complete in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018
Phase 3 registration program in VVC planned for the fourth quarter of 2018
IV SCY-078 program continues to advance; Phase 1 study with liposomal formulation expected to initiate in the third quarter of 2018
JERSEY CITY, N.J., May 8, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended March 31, 2018, and provided an update on recent operational and clinical developments.
"The first quarter of 2018 was one of significant clinical progress in what has the potential to be a transformative year for SCYNEXIS with multiple anticipated milestones," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "We remain on track to report top-line data from the Phase 2b, dose-finding study evaluating oral SCY-078 for the treatment of vulvovaginal candidiasis (VVC) by July 2018, with Phase 3 initiation planned for the fourth quarter. We also anticipate continued progress toward expanding the therapeutic utility of SCY-078 with the planned initiation of clinical trials in invasive candidiasis and invasive aspergillosis in the second half of the year, as well as the advancement of our programs targeting refractory invasive fungal infections. We are well-positioned to realize the promise of SCY-078 as a potent and versatile antifungal agent."
Clinical and Regulatory Update for Lead Program – SCY-078 as a Treatment for VVC
•In May 2018, SCYNEXIS announced it has completed enrollment in the Phase 2b, dose-finding study of oral SCY-078 for the treatment of VVC (the DOVE study). SCYNEXIS is on-track to announce top-line data by July 2018. Following successful dose-identification from this trial, SCYNEXIS plans to initiate a Phase 3 registration program of oral SCY-078 in VVC in the fourth quarter of 2018, with potential NDA filing for VVC expected in 2020.
•In May 2018, SCYNEXIS announced the receipt of Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. Food and Drug Administration (FDA) for the treatment of VVC and prevention of recurrent VVC. The QIDP designation allows SCYNEXIS to have priority review and an additional five years of market exclusivity in the U.S. for SCY-078. The FDA's Fast Track Drug Development Program is a process designed to facilitate the development and expeditious review of drugs to treat serious conditions and fill unmet medical needs.
Continued Advancement of IV SCY-078 Program with Liposomal Formulation
•Pre-clinical work on the liposomal IV formulation of SCY-078 continues, and SCYNEXIS remains on track to initiate a Phase 1 trial evaluating the safety and tolerability of this formulation in healthy volunteers in the third quarter of 2018.
•If successful, following completion of the Phase 1 study and pending FDA review, SCYNEXIS plans to initiate a Phase 2b, IV-oral step-down study of SCY-078 in invasive candidiasis patients with the liposomal IV and oral formulations of SCY-078 in the fourth quarter of 2018.
Pre-clinical Data Support Continued Development of SCY-078 for Invasive Fungal Infections
•In April 2018, at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), SCYNEXIS presented pre-clinical data demonstrating SCY-078's potent antifungal activity against Aspergillus spp., including azole-resistant isolates, as well as synergistic activity with approved antifungals against Aspergillus strains. Additionally, SCYNEXIS presented in vivo data in a mouse model of Pneumocystis pneumonia that demonstrated the activity of SCY-078 as determined by improved survival and reduction of fungal burden, supporting future development for prophylaxis indications.
•In March 2018, at Superbugs and Superdrugs 2018, SCYNEXIS presented pre-clinical data demonstrating the inhibitory effect of SCY-078 against Candida auris biofilms, as well as SCY-078's ability to affect the ultrastructure of C. auris cells and interrupt cell division.
•In February 2018, at the 8th Advances Against Aspergillosis, SCYNEXIS presented new pre-clinical data demonstrating synergistic in vivo activity and improved outcomes of SCY-078 in combination with isavuconazole for the treatment of invasive pulmonary aspergillosis. The Company plans to initiate a Phase 2 study in the third quarter of 2018 to test the clinical efficacy of oral SCY-078 in combination with standard of care for the treatment of invasive aspergillosis.
•All posters and presentations are available on the Scientific Publications page of the SCYNEXIS website.
Corporate Update
•In April 2018, SCYNEXIS received confirmation of the renewal of its Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA). With this designation, SCYNEXIS is eligible to receive financial incentives, regulatory fee reductions and waivers, and European Union funding. SCYNEXIS remains committed to the European market and has designed its registration programs such that concurrent FDA and EMA approvals would be possible. European sites are actively enrolling in the FURI study, a global, open-label study, designed to evaluate oral SCY-078 for the treatment of fungal infections that are refractory to or intolerant of standard therapies.
•On March 8, 2018, SCYNEXIS raised $30.0 million in gross proceeds by issuing 17,751,500 shares of the Company's common stock and two series of warrants to purchase up to an aggregate of 21,301,800 shares of the Company's common stock. The offering resulted in approximately $27.9 million of net proceeds after deducting the underwriting discount and estimated offering expenses.
First Quarter 2018 Financial Results
Cash and cash equivalents and short-term investments totaled $63.7 million as of March 31, 2018, with net working capital of $53.5 million.
Research and development expenses increased to $5.3 million in the first quarter of 2018, compared to $4.0 million in the first quarter of 2017. The increase of $1.3 million, or 33%, was primarily driven by an increase of $0.7 million in pre-clinical development expense, a $0.7 million increase in clinical development expense, a $0.4 million increase in chemistry, manufacturing, and controls (CMC), and a net increase of $0.2 million in other research and development costs; offset by a decrease in consulting expense of $0.7 million.
Selling, general and administrative expenses of $2.0 million in the first quarter of 2018 were consistent compared to the selling, general and administrative expenses of $2.1 million in the first quarter of 2017.
Total other income increased to $3.2 million in the first quarter of 2018 due to a $3.6 million non-cash gain recorded on the fair value adjustment of the warrant liabilities.
Net loss for the first quarter of 2018 was $4.0 million, or $0.12 basic net loss per share. This compares to a net loss for the first quarter of 2017 of $4.9 million, or $0.19 basic net loss per share.
SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update
PR NewswireMay 8, 2018
Enrollment complete in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018
Phase 3 registration program in VVC planned for the fourth quarter of 2018
IV SCY-078 program continues to advance; Phase 1 study with liposomal formulation expected to initiate in the third quarter of 2018
JERSEY CITY, N.J., May 8, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended March 31, 2018, and provided an update on recent operational and clinical developments.
"The first quarter of 2018 was one of significant clinical progress in what has the potential to be a transformative year for SCYNEXIS with multiple anticipated milestones," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "We remain on track to report top-line data from the Phase 2b, dose-finding study evaluating oral SCY-078 for the treatment of vulvovaginal candidiasis (VVC) by July 2018, with Phase 3 initiation planned for the fourth quarter. We also anticipate continued progress toward expanding the therapeutic utility of SCY-078 with the planned initiation of clinical trials in invasive candidiasis and invasive aspergillosis in the second half of the year, as well as the advancement of our programs targeting refractory invasive fungal infections. We are well-positioned to realize the promise of SCY-078 as a potent and versatile antifungal agent."
Clinical and Regulatory Update for Lead Program – SCY-078 as a Treatment for VVC
•In May 2018, SCYNEXIS announced it has completed enrollment in the Phase 2b, dose-finding study of oral SCY-078 for the treatment of VVC (the DOVE study). SCYNEXIS is on-track to announce top-line data by July 2018. Following successful dose-identification from this trial, SCYNEXIS plans to initiate a Phase 3 registration program of oral SCY-078 in VVC in the fourth quarter of 2018, with potential NDA filing for VVC expected in 2020.
•In May 2018, SCYNEXIS announced the receipt of Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. Food and Drug Administration (FDA) for the treatment of VVC and prevention of recurrent VVC. The QIDP designation allows SCYNEXIS to have priority review and an additional five years of market exclusivity in the U.S. for SCY-078. The FDA's Fast Track Drug Development Program is a process designed to facilitate the development and expeditious review of drugs to treat serious conditions and fill unmet medical needs.
Continued Advancement of IV SCY-078 Program with Liposomal Formulation
•Pre-clinical work on the liposomal IV formulation of SCY-078 continues, and SCYNEXIS remains on track to initiate a Phase 1 trial evaluating the safety and tolerability of this formulation in healthy volunteers in the third quarter of 2018.
•If successful, following completion of the Phase 1 study and pending FDA review, SCYNEXIS plans to initiate a Phase 2b, IV-oral step-down study of SCY-078 in invasive candidiasis patients with the liposomal IV and oral formulations of SCY-078 in the fourth quarter of 2018.
Pre-clinical Data Support Continued Development of SCY-078 for Invasive Fungal Infections
•In April 2018, at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), SCYNEXIS presented pre-clinical data demonstrating SCY-078's potent antifungal activity against Aspergillus spp., including azole-resistant isolates, as well as synergistic activity with approved antifungals against Aspergillus strains. Additionally, SCYNEXIS presented in vivo data in a mouse model of Pneumocystis pneumonia that demonstrated the activity of SCY-078 as determined by improved survival and reduction of fungal burden, supporting future development for prophylaxis indications.
•In March 2018, at Superbugs and Superdrugs 2018, SCYNEXIS presented pre-clinical data demonstrating the inhibitory effect of SCY-078 against Candida auris biofilms, as well as SCY-078's ability to affect the ultrastructure of C. auris cells and interrupt cell division.
•In February 2018, at the 8th Advances Against Aspergillosis, SCYNEXIS presented new pre-clinical data demonstrating synergistic in vivo activity and improved outcomes of SCY-078 in combination with isavuconazole for the treatment of invasive pulmonary aspergillosis. The Company plans to initiate a Phase 2 study in the third quarter of 2018 to test the clinical efficacy of oral SCY-078 in combination with standard of care for the treatment of invasive aspergillosis.
•All posters and presentations are available on the Scientific Publications page of the SCYNEXIS website.
Corporate Update
•In April 2018, SCYNEXIS received confirmation of the renewal of its Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA). With this designation, SCYNEXIS is eligible to receive financial incentives, regulatory fee reductions and waivers, and European Union funding. SCYNEXIS remains committed to the European market and has designed its registration programs such that concurrent FDA and EMA approvals would be possible. European sites are actively enrolling in the FURI study, a global, open-label study, designed to evaluate oral SCY-078 for the treatment of fungal infections that are refractory to or intolerant of standard therapies.
•On March 8, 2018, SCYNEXIS raised $30.0 million in gross proceeds by issuing 17,751,500 shares of the Company's common stock and two series of warrants to purchase up to an aggregate of 21,301,800 shares of the Company's common stock. The offering resulted in approximately $27.9 million of net proceeds after deducting the underwriting discount and estimated offering expenses.
First Quarter 2018 Financial Results
Cash and cash equivalents and short-term investments totaled $63.7 million as of March 31, 2018, with net working capital of $53.5 million.
Research and development expenses increased to $5.3 million in the first quarter of 2018, compared to $4.0 million in the first quarter of 2017. The increase of $1.3 million, or 33%, was primarily driven by an increase of $0.7 million in pre-clinical development expense, a $0.7 million increase in clinical development expense, a $0.4 million increase in chemistry, manufacturing, and controls (CMC), and a net increase of $0.2 million in other research and development costs; offset by a decrease in consulting expense of $0.7 million.
Selling, general and administrative expenses of $2.0 million in the first quarter of 2018 were consistent compared to the selling, general and administrative expenses of $2.1 million in the first quarter of 2017.
Total other income increased to $3.2 million in the first quarter of 2018 due to a $3.6 million non-cash gain recorded on the fair value adjustment of the warrant liabilities.
Net loss for the first quarter of 2018 was $4.0 million, or $0.12 basic net loss per share. This compares to a net loss for the first quarter of 2017 of $4.9 million, or $0.19 basic net loss per share.
Allegati
cash15
...nessun titolo...
- Registrato
- 17/1/15
- Messaggi
- 5.341
- Punti reazioni
- 294
aldilà delle follie del management che credo sia tra i peggiori
la pipeline ha un valore enorme che potrebbe portare la societò a vlori stellari, la candida auris è un vero problema ma se non passa l'uso endovena vale ben poco...
unico dubbio mio, che si aggiunge al valore pessimo del management (speculatori e non imprenditori biotech veri), è determinato dal fatto che la pipeline è un principio che stava testando anni fa il colosso MSD...
...mi chiedo, possibile che un colosso che ha 10000 volte potenza economica e quindi percorsi di ingegnerizzazione delle molecole farmacologiche mostruosamente efficaci si lascino scappare una pipeline così performante?
boh
comunque bel giocattolo per fare botti verso l'alto e verso il basso... al momento
la pipeline ha un valore enorme che potrebbe portare la societò a vlori stellari, la candida auris è un vero problema ma se non passa l'uso endovena vale ben poco...
unico dubbio mio, che si aggiunge al valore pessimo del management (speculatori e non imprenditori biotech veri), è determinato dal fatto che la pipeline è un principio che stava testando anni fa il colosso MSD...
...mi chiedo, possibile che un colosso che ha 10000 volte potenza economica e quindi percorsi di ingegnerizzazione delle molecole farmacologiche mostruosamente efficaci si lascino scappare una pipeline così performante?
boh
comunque bel giocattolo per fare botti verso l'alto e verso il basso... al momento
SCYX | SharpChart | StockCharts.com
SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences
Taglietti Marco Chief Executive Officer Aug 23 Buy 1.29 25,000 32,250 429,000 Aug 27 08:29 AM
Angulo Gonzalez David Chief Medical Officer Mar 29 Buy 1.36 6,000 8,160 101,790 Apr 02 08:10 AM
Sukenick Scott General Counsel Mar 08 Buy 1.69 2,959 5,001 2,959 Mar 12 08:51 AM
HASTINGS DAVID C Director Mar 08 Buy 1.69 11,834 19,999 31,834 Mar 12 08:52 AM
Taglietti Marco Chief Executive Officer Mar 08 Buy 1.69 100,000 169,000 404,000 Mar 12 08:50 AM
Francois Eric Chief Financial Officer Mar 08 Buy 1.69 5,917 10,000 24,917 Mar 12 08:49 AM
Angulo Gonzalez David Chief Medical Officer Mar 08 Buy 1.69 14,790 24,995 88,790 Mar 12 08:48 AM
Angulo Gonzalez David Chief Medical Officer Mar 08 Buy 1.39 7,000 9,730 95,790 Mar 12 04:43 PM
SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences
Taglietti Marco Chief Executive Officer Aug 23 Buy 1.29 25,000 32,250 429,000 Aug 27 08:29 AM
Angulo Gonzalez David Chief Medical Officer Mar 29 Buy 1.36 6,000 8,160 101,790 Apr 02 08:10 AM
Sukenick Scott General Counsel Mar 08 Buy 1.69 2,959 5,001 2,959 Mar 12 08:51 AM
HASTINGS DAVID C Director Mar 08 Buy 1.69 11,834 19,999 31,834 Mar 12 08:52 AM
Taglietti Marco Chief Executive Officer Mar 08 Buy 1.69 100,000 169,000 404,000 Mar 12 08:50 AM
Francois Eric Chief Financial Officer Mar 08 Buy 1.69 5,917 10,000 24,917 Mar 12 08:49 AM
Angulo Gonzalez David Chief Medical Officer Mar 08 Buy 1.69 14,790 24,995 88,790 Mar 12 08:48 AM
Angulo Gonzalez David Chief Medical Officer Mar 08 Buy 1.39 7,000 9,730 95,790 Mar 12 04:43 PM
VENDUTE IERI E RIMESSO OGGI
MA STI PEXXI DI M. FIGURATI SE MI SERVONO
SCYNEXIS Eseguito Parziale Acquisto 4.500
1.600 0,67 0,67 NASDAQ 30/01/2019 15:44:19 SL TP R
CHE POI STO SCHIFO DI FINECO MI DA COME MINIMO 0,6701
#VOMITEVOLEFINECO
MA STI PEXXI DI M. FIGURATI SE MI SERVONO
SCYNEXIS Eseguito Parziale Acquisto 4.500
1.600 0,67 0,67 NASDAQ 30/01/2019 15:44:19 SL TP R
CHE POI STO SCHIFO DI FINECO MI DA COME MINIMO 0,6701
#VOMITEVOLEFINECO
- Registrato
- 18/4/18
- Messaggi
- 909
- Punti reazioni
- 27
VENDUTE IERI E RIMESSO OGGI
MA STI PEXXI DI M. FIGURATI SE MI SERVONO
SCYNEXIS Eseguito Parziale Acquisto 4.500
1.600 0,67 0,67 NASDAQ 30/01/2019 15:44:19 SL TP R
CHE POI STO SCHIFO DI FINECO MI DA COME MINIMO 0,6701
#VOMITEVOLEFINECO
ma fineco non ha il book complet ma quello di qualche fornitore USA...
lo si sa da sempre
non è questo il punto che ben so avendo aperto per primo anni fa la discussione
il punto è che se sul book appunto mi da minimo 6701 e poi mi trovo un eseguito a 67 c'è molto che non va in fineco
cmq in after 1,45 + 101%
alla faccia di paulista il guru che segnala + 30 e scriveva che io i 20% intra me li sogno
a qualcuno l'ho segnalata in m.p spero che ne abbia prese un po invece di quel cexx di MNGA
- Registrato
- 18/4/18
- Messaggi
- 909
- Punti reazioni
- 27
allafacciadelbicarbonatodisodio +100%
faranno adc o scende perche i dati finali son previsti a fine 2019?il problema a breve nel mondo sanitario sono MDR e C. auris?
SCY ha la soluzione del secondo problema..
SCY esplode
peccato, da 0,38 che seguo ma come al solito, aspetta aspetta e questa vola vola vola
SCY ha la soluzione del secondo problema..
SCY esplode
peccato, da 0,38 che seguo ma come al solito, aspetta aspetta e questa vola vola vola